News headlines about Celldex Therapeutics (NASDAQ:CLDX) have been trending positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Celldex Therapeutics earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 49.2863013604298 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Celldex Therapeutics, Inc., (NASDAQ: CLDX) – Which Option is Best? – Buy or Sell – Stock Watch (stocksnewstimes.com)
- Is the Stock In Play? – Celldex Therapeutics Inc (NASDAQ: CLDX) – Alpha Beta Stock (alphabetastock.com)
- Celldex Therapeutics, Inc. (CLDX) Summary of Price Movements – The Stocks News (press release) (thestocksnews.com)
- Analysts Expect Celldex Therapeutics, Inc. (CLDX) Will Announce Quarterly Sales of $2.42 Million (americanbankingnews.com)
- Buy Analyst Rating?: Celldex Therapeutics, Inc. (CLDX) – Nasdaq Chronicle (nasdaqchronicle.com)
CLDX has been the topic of several analyst reports. HC Wainwright set a $10.00 target price on Celldex Therapeutics and gave the company a “buy” rating in a research note on Friday, February 9th. WBB Securities reiterated a “buy” rating and issued a $10.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, December 6th. Cantor Fitzgerald reiterated a “buy” rating and issued a $9.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, March 7th. BidaskClub upgraded Celldex Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 6th. Finally, Leerink Swann reiterated a “market perform” rating and issued a $3.00 target price (down previously from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, March 8th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $6.38.
Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.08. Celldex Therapeutics had a negative return on equity of 44.64% and a negative net margin of 730.06%. The business had revenue of $3.50 million for the quarter, compared to analyst estimates of $1.49 million. During the same quarter in the previous year, the firm earned ($0.30) earnings per share. The company’s revenue was up 87.2% on a year-over-year basis. equities analysts anticipate that Celldex Therapeutics will post -0.78 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by BBNS and is owned by of BBNS. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://baseballnewssource.com/2018/03/21/favorable-media-coverage-somewhat-unlikely-to-impact-celldex-therapeutics-cldx-share-price/1923390.html.
About Celldex Therapeutics
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.